Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma
Tomokazu Kawaoka
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorCorresponding Author
Hiroshi Aikata
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Correspondence: Dr Hiroshi Aikata, Department of Gastroenterology and Metabolism,Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. Email: [email protected]Search for more papers by this authorTomoki Kobayashi
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorShinsuke Uchikawa
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorKazuki Ohya
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorKenichiro Kodama
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorYuno Nishida
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorKana Daijo
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorMitsutaka Osawa
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorYuji Teraoka
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorYuki Inagaki
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorFumi Honda
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorMasahiro Hatooka
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorKei Morio
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorReona Morio
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorHatsue Fujino
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorTakashi Nakahara
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorEisuke Murakami
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorMasataka Tsuge
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorAkira Hiramatsu
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorMichio Imamura
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorYoshiiku Kawakami
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorYasutaka Baba
Department of Diagnostic Radiology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
Search for more papers by this authorKazuo Awai
Department of Diagnostic Radiology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
Search for more papers by this authorKazuaki Chayama
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Liver Research Project Center, Hiroshima University, Hiroshima, Japan
Search for more papers by this authorTomokazu Kawaoka
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorCorresponding Author
Hiroshi Aikata
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Correspondence: Dr Hiroshi Aikata, Department of Gastroenterology and Metabolism,Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. Email: [email protected]Search for more papers by this authorTomoki Kobayashi
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorShinsuke Uchikawa
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorKazuki Ohya
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorKenichiro Kodama
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorYuno Nishida
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorKana Daijo
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorMitsutaka Osawa
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorYuji Teraoka
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorYuki Inagaki
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorFumi Honda
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorMasahiro Hatooka
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorKei Morio
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorReona Morio
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorHatsue Fujino
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorTakashi Nakahara
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorEisuke Murakami
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorMasataka Tsuge
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorAkira Hiramatsu
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorMichio Imamura
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorYoshiiku Kawakami
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Search for more papers by this authorYasutaka Baba
Department of Diagnostic Radiology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
Search for more papers by this authorKazuo Awai
Department of Diagnostic Radiology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
Search for more papers by this authorKazuaki Chayama
Department of Gastroenterology and Metabolism, Hiroshima University Hospital, Hiroshima, Japan
Liver Research Project Center, Hiroshima University, Hiroshima, Japan
Search for more papers by this authorAbstract
Aim
The aim of this study is to compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) between 5-fluorouracil (5-FU)-based continuous infusion chemotherapy and low-dose cisplatin (CDDP) monotherapy in patients with advanced hepatocellular carcinoma (HCC).
Methods
Patients were grouped according to HAIC regimen (5-FU group, n = 317/CDDP group, n = 66). A two-to-one match was created using propensity score analysis (5-FU group, n = 102/CDDP group, n = 51). After matching, response rate (RR) and adverse events as primary end-points, and survival and progression-free survival as secondary end-points, were analyzed.
Results
In the analysis of primary end-points, the RR in the 5-FU group was significantly higher than in the CDDP group (32.4% vs. 15.7%, P = 0.033). In patients with a Child–Pugh (CP) score of 5–7, the RR in the 5-FU group was significantly higher than that in the CDDP group (36.1% vs. 15.4%, P = 0.020). In those with a CP score of 8–9, there was no significant difference in RR between the two groups (15.8% vs. 16.6%, P = 1.000). The reservoir system-related complications were 9.8% in the 5-FU group, and there was no significant difference in the incidence of grade 3/4 adverse events between the two matched groups (P > 0.05).
In terms of secondary end-points, the median survival time was 9.1 and 8.7 months for the 5-FU and CDDP groups, respectively (P = 0.4917). Progression-free survival was 3.9 months for the 5-FU group and 4.9 months for the CDDP group (P = 0.4).
Conclusions
5-Fluorouracil-based continuous infusion chemotherapy could be suitable for advanced HCC patients with a CP score of 5–7 considering the treatment response.
References
- 1Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–2917.
- 2Bolondi L, Sofia S, Siringo S et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48: 251–259.
- 3Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429–442.
- 4Kudo M, Izumi N, Kokudo N et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339–364.
- 5Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–390.
- 6Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25–34.
- 7Jeong SW, Jang JY, Shim KY et al. Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis. Gut Liver 2013; 7: 696–703.
- 8Ueshima K, Kudo M, Takita M et al. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology 2010; 78(Suppl 1): 148–153.
- 9Obi S, Yoshida H, Toune R et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990–1997.
- 10Ando E, Tanaka M, Yamashita F et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588–595.
- 11Yamasaki T, Sakaida I. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders. Hepatol Res 2012; 42: 340–348.
- 12Monden M, Sakon M, Sakata Y, Ueda Y, Hashimura E, Group FR. 5-Fluorouracil arterial infusion + interferon therapy for highly advanced hepatocellular carcinoma: A multicenter, randomized, phase II study. Hepatol Res 2012; 42: 150–165.
- 13Yamashita T, Arai K, Sunagozaka H et al. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology 2011; 81: 281–290.
- 14Ensminger WD, Gyves JW. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 1983; 10: 176–182.
- 15Nouso K, Miyahara K, Uchida D et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer 2013; 109: 1904–1907.
- 16Arii S, Sata M, Sakamoto M et al. Management of hepatocellular carcinoma: report of consensus meeting in the 45th annual meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010; 40: 667–685.
- 17Kudo M, Kitano M, Sakurai T, Nishida N. General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the Liver Cancer Study Group of Japan. Dig Dis 2015; 33: 765–770.
- 18Katamura Y, Aikata H, Kimura Y et al. Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. J Gastroenterol Hepatol 2010; 25: 1117–1122.
- 19Miyaki D, Aikata H, Honda Y et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification. J Gastroenterol Hepatol 2012; 27: 1850–1857.
- 20Miyaki D, Aikata H, Kan H et al. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. J Gastroenterol Hepatol 2013; 28: 1834–1841.
- 21Uka K, Aikata H, Takaki S et al. Similar effects of recombinant interferon-alpha-2b and natural interferon-α when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. Liver Int 2007; 27: 1209–1216.
- 22Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247.
- 23Clavien PA, Barkun J, de Oliveira ML et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250: 187–196.
- 24Zinsmeister AR, Connor JT. Ten common statistical errors and how to avoid them. Am J Gastroenterol 2008; 103: 262–266.
- 25Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med 2013; 32: 2837–2849.
- 26Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330–338.
- 27Stehlin JS Jr, de Ipolyi PD, Greeff PJ, McGaff CJ Jr, Davis BR, McNary L. Treatment of cancer of the liver. twenty years’ experience with infusion and resection in 414 patients. Ann Surg 1988; 208: 23–35.
- 28Doci R, Bignami P, Bozzetti F et al. Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer 1988; 61: 1983–1987.
10.1002/1097-0142(19880515)61:10<1983::AID-CNCR2820611009>3.0.CO;2-V CAS PubMed Web of Science® Google Scholar
- 29Iwamiya T, Sawada S, Ohta Y. Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol 1994; 33(Suppl): S134–S138.
- 30Ikeda M, Okusaka T, Furuse J et al. A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol 2013; 72: 463–470.
- 31Nishiyama M, Yamamoto W, Park JS et al. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res 1999; 5: 2620–2628.
- 32Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 50: 3473–3486.
- 33Sakon M, Nagano H, Dono K et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435–442.
- 34Court WS, Order SE, Siegel JA et al. Remission and survival following monthly intraarterial cisplatinum in nonresectable hepatoma. Cancer Invest 2002; 20: 613–625.
- 35Nagai H, Matsui T, Kanayama M et al. Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2010; 66: 1123–1129.
- 36Zwelling LA, Michaels S, Schwartz H, Dobson PP, Kohn KW. DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum (II) and L-phenylalanine mustard. Cancer Res 1981; 41: 640–649.
- 37Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409–422.
- 38Nagasue N, Yukaya H, Okamura J et al. Intra-arterial administration of epirubicin in the treatment of non-resectable hepatocellular carcinoma. Epirubicin Study Group for Hepatocellular Carcinoma. Gan To Kagaku Ryoho 1986; 13: 2786–2792 (In Japanese.).
- 39Shepherd FA, Evans WK, Blackstein ME et al. Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma. J Clin Oncol 1987; 5: 635–640.
- 40Makela J, Tikkakoski T, Leinonen A, Siniluoto T, Karttunen A, Kairaluoma MI. Superselective intra-arterial chemotherapy with mitomycin C in hepatic neoplasms. Eur J Surg Oncol 1993; 19: 348–354.
- 41Gayat E, Pirracchio R, Resche-Rigon M, Mebazaa A, Mary JY, Porcher R. Propensity scores in intensive care and anaesthesiology literature: a systematic review. Intensive Care Med 2010; 36: 1993–2003.
Citing Literature
